许可协议支持临床前药物项目

An agreement for the use of two commercial licences for Horizon’s proprietary GS knockout CHO cell line has been signed by Shanghai-based Sanyou Biopharmaceuticals Co. Ltd, for development of pre-clinical antibody drug projects and to support its customers’ human biotherapeutic products, as well as offering the platform through its contract research services.

“ Sanyou是一家领先的生物技术公司，在早期药物发现，IND申请和临床试验管理方面拥有丰富的经验。该公司已经建立了一项综合的创新抗体研发实验室，我们很高兴Chosource被选中以支持其生物治疗管道和合同研究服务。“ Horizo​​n致力于支持各种规模的创新组织，以使用我们的表达平台来增强生物治疗生产的能力。我们很荣幸能获得授权的Chosource到80多个组织，从非营利性和早期初创公司到临床阶段生物技术和大型制药公司，并帮助启用了在这些细胞中表达的至少8种生物治疗剂，以发展为临床试验。”

Dr. David Lang, CEO, Sanyou Biopharmaceuticals Co., Ltd., said: “Horizon’s CHOSOURCE facilitates the development of stable cell lines for the expression of antibodies and other recombinant proteins, and is recognised in the industry and by regulators for high yield manufacturing. This robust platform will be key in enabling us to generate stable cell lines for the development of antibody drugs, diagnostic products and cell therapy-related components, and allow us to provide a stronger one-stop solution to our clients with IND ready projects through our contract research services and pipeline-enriching collaborations.”